Peptide
HGH Fragment 176-191
SaveA synthetic fragment of human growth hormone (amino acids 176-191) studied for lipolytic effects without the growth-promoting or diabetogenic actions of full hGH.
Quick verdict
Preclinical data show lipolytic activity. Closely related to AOD-9604. Limited human evidence and no regulatory approval.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
In-vitro and animal studies show fat-metabolism effects. The closely related AOD-9604 failed its phase IIb obesity trial. Standalone human data are sparse.
Benefits
- Lipolytic activity without IGF-1 elevation in preclinical data
- Does not appear to cause insulin resistance like full hGH
Dosage notes
Community protocols: 250–500 mcg subcutaneously daily. Not clinically validated.
Side effects
- Injection-site irritation
- Possible hypoglycemia
- Unknown long-term effects
Who should be cautious
Not approved for human use. Gray-market products may be mislabeled AOD-9604 or impure.
What this page cannot tell you
The parent compound AOD-9604 failed clinical trials for weight loss. Extrapolation to this fragment is uncertain.
Leaderboard scores
- Weight loss25
Write a review
Sign in to write a review.